TRIM11 antibody

E3 ubiquitin-protein ligase that promotes the degradation of insoluble ubiquitinated proteins, including insoluble PAX6, poly-Gln repeat expanded HTT and poly-Ala repeat expanded ARX. Mediates PAX6 ubiquitination leading to proteasomal degradation, thereby modulating cortical neurogenesis. May also inhibit PAX6 transcriptional activity, possibly in part by preventing the binding of PAX6 to its consensus sequences. May contribute to the regulation of the intracellular level of HN (humanin) or HN-containing proteins through the proteasomal degradation pathway. Mediates MED15 ubiquitination leading to proteasomal degradation. May contribute to the innate restriction of retroviruses. Upon overexpression, reduces HIV-1 and murine leukemia virus infectivity, by suppressing viral gene expression. Antiviral activity depends on a functional E3 ubiquitin-protein ligase domain. May regulate TRIM5 turnover via the proteasome pathway, thus counteracting the TRIM5-mediated cross-species restriction of retroviral infection at early stages of the retroviral life cycle.

E3 ubiquitin-protein ligase TRIM11|Protein BIA1|RING finger protein 92|Tripartite motif-containing protein 11|TRIM11|RNF92

81559

Q96F44

Human, Mouse

Tripartite motif-containing 11

TRIM11

ELISA, WB, IHC

Epigenetics, Immunology, Metabolism

Immunogen affinity purified

WB: 1:200-1:1000; IHC: 1:20-1:200

≥95% as determined by SDS-PAGE

Liquid

52 kDa

PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months (Avoid repeated freeze / thaw cycles.)